United Therapeutics Corporation (UTHR)

About United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

As of November 3, 2026, United Therapeutics Corporation (UTHR) stock rose to $600.83, up 0.79% (+$4.69) versus the previous close. On the day, shares have traded between $596.14 and $606.16. That puts UTHR near the top of its 52-week range of $430.02 to $609.99. United Therapeutics Corporation operates in the pharmaceutical preparations space and carries a market capitalization of roughly $25.68 billion, with about 272.3K shares changing hands.

Latest UTHR news

• iShares Core S&P Mid-Cap (IJH) Adds Okta and TechnipFMC on Oct. 29Yahoo Finance· Nov 2, 6:06 AM ETIJH
• SGIOY vs. UTHR: Which Stock Is the Better Value Option?Yahoo Finance· Oct 30, 10:40 AM ET
• OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance· Oct 30, 7:50 AM ETOABI
• Why Did Insmed Stock Jump?trefis.com· Oct 30, 7:15 AM ET
• United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension TherapyYahoo Finance· Oct 29, 4:12 PM ET
• Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”tikr.com· Oct 29, 2:40 PM ET
• Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineYahoo Finance· Oct 29, 9:00 AM ETCOLL
• United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatmentinvestorshub.advfn.com· Oct 28, 11:26 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want UTHR headlines, alerts and AI research in one place? Create a free account →

• $MNKD $UTHR reporting Q3 tomorrow morning should provide a bit of insight to our Thursday report. Exciting times ahead.

  @amsteliam· Nov 3, 12:14 PM ET· Bullish

• @Myd273 $UTHR $MNKD SMI is likely being developed for COPD, not primarily to recapture the 3% who drop TreT due to cough. Credit: @ItzaFugazi

  @clan2pointOh· Nov 2, 7:40 PM ET· Bullish

• $MNKD $UTHR | AERO LAB INSTITUTIONAL RESEARCH JEFFERIES LONDON: THREE PRESENTATIONS, TWO COMPANIES, ONE INVESTMENT THESIS November 16–18 could offer an important opportunity to evaluate the next phase of MannKind’s growth story. The sequence: • Nov 16: MNKD management presenta…

  @Michaelluh· Nov 2, 11:08 AM ET· Bullish

• @Kuka @Nakom SMI is not being resurrected to capture the mere 3% of Tyvaso DPI users who stop using due to cough, but, instead, is being created to capture the COPD market; still years away from availability. $UTHR wants to be all products for all patients.

  @clan2pointOh· Nov 2, 8:44 AM ET· Bullish

• $MNKD $UTHR .....nicely done! https://x.com/st_boardroomx/status/2115799054156251351?s=43

  @Outcomes· Oct 31, 1:08 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →